Can oral Fusobacterium nucleatum move to the gut and drive intestinal dysbiosis and inflammation?

The migration of oral bacteria to the gastrointestinal tract is a well-documented biological phenomenon that significantly impacts gut health. Evidence from genomic and clinical studies confirms that Fusobacterium nucleatum (Fn) and other oral pathobionts can bypass the gastric acid barrier to colonize the intestines, where they actively drive pathological changes.

Evidence for oral-to-gut translocation

Translocation occurs through two primary pathways: the enteral route (swallowing) and the hematogenous route (the bloodstream). Research using genomic sequencing has definitively linked the two sites, finding identical strains of F. nucleatum in the oral cavity and colorectal tumor tissues of the same patients.

• Survival mechanisms: To survive the harsh environment of the stomach (pH as low as 1.5), F. nucleatum utilizes the FnFabM gene to modify its cell membrane with erucic acid, providing acid resistance.
• Prevalence: Oral strains of Fn have been detected in the rectal microbiota of approximately 67% of healthy individuals, sometimes accounting for up to 9% of the local microbial community.
• Facilitating factors: The use of proton pump inhibitors (PPIs) and the presence of oral dysbiosis (like periodontitis) increase the microbial load reaching the gut by weakening the gastric acid barrier.

Impact on intestinal dysbiosis

Once established in the gut, F. nucleatum acts as a "driver" of dysbiosis, fundamentally altering the microbial landscape.

• Microbial diversity: Clinical models show that Fn overgrowth significantly reduces alpha diversity (the richness and evenness of bacterial species).
• Biofilm formation: Utilizing adhesins like FadA and Fap2, Fn forms robust biofilms on the intestinal mucosa. This creates a protective niche that favors other pathogens while displacing beneficial, commensal bacteria.

Mechanisms of inflammation and disease

F. nucleatum does not merely sit in the gut; it actively triggers inflammatory cascades and compromises the intestinal barrier.

• Molecular signaling: Fn releases outer membrane vesicles (OMVs) that activate the TLR4-NF-κB signaling pathway. This leads to the overproduction of pro-inflammatory cytokines, including IL-6, IL-8, and TNF.
• Epithelial disruption: The FadA adhesin binds to E-cadherin on intestinal epithelial cells, which not only activates oncogenic signaling but also weakens the tight junctions that maintain the gut barrier.
• Immune dysregulation: Fn induces dendritic cell activation and promotes a Th17/Treg cell imbalance. This shift toward a pro-inflammatory state is a hallmark of ulcerative colitis and the progression of colitis-associated colorectal cancer.

Bottom line

The claim is strongly supported by science. Fusobacterium nucleatum translocates from the mouth to the gut via swallowing or the bloodstream, where it survives gastric acid to colonize the mucosa. Once present, it actively contributes to intestinal dysbiosis and triggers chronic inflammation through TLR4/NF-κB signaling and epithelial barrier disruption.